These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31340438)

  • 1. Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity.
    Baiden-Amissah REM; Tuyaerts S
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intimate relationship between gut microbiota and cancer immunotherapy.
    Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
    Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
    Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
    Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 8. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 14. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
    Hou F; Pan Z; Yang R; Zhi F; Bi Y
    J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.
    Luo Q; Zhang L; Luo C; Jiang M
    Cancer Lett; 2019 Jul; 454():191-203. PubMed ID: 30998963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota Manipulated to Enhance Immunity.
    Cancer Discov; 2019 Jul; 9(7):822. PubMed ID: 31072874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
    O'Neill RE; Cao X
    Adv Cancer Res; 2019; 143():145-194. PubMed ID: 31202358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.